Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALAB1643

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1   Web Page for STN Seminar Schedule - N. America
NEWS 2 DEC 01 ChemPort single article sales feature unavailable
NEWS 3 JUN 01 CAS REGISTRY Source of Registration (SR) searching
         enhanced on STN
NEWS 4 JUN 26 NUTRACEUT and PHARMAML no longer updated
NEWS 5 JUN 29 IMSCOPROFILE now reloaded monthly
NEWS 6 JUN 29 EPFULL adds Simultaneous Left and Right Truncation
         (SLART) to AB, MCLM, and TI fields
NEWS 7 JUL 09 PATDPAFULL adds Simultaneous Left and Right
         Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS 8 JUL 14 USGENE enhances coverage of patent sequence location
         (PSL) data
NEWS 9 JUL 27 CA/CAplus enhanced with new citing references
NEWS 10 JUL 16 GBFULL adds patent backfile data to 1855
NEWS 11 JUL 21 USGENE adds bibliographic and sequence information
NEWS 12 JUL 28 EPFULL adds first-page images and applicant-cited
         references
NEWS 13 JUL 28 INPADOCDB and INPAFAMDB add Russian legal status data
NEWS 14 AUG 08 Improve STN by completing a survey and be entered to
         win a gift card
NEWS 15 AUG 10 Time limit for inactive STN sessions doubles to 40
         minutes
NEWS 16 AUG 17 CAS REGISTRY, the Global Standard for Chemical
         Research, Approaches 50 Millionth Registration
         Milestone
NEWS 17 AUG 18 COMPENDEX indexing changed for the Corporate Source
         (CS) field

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
     AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS   STN Operating Hours Plus Help Desk Availability
NEWS LOGIN   Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

 All use of STN is subject to the provisions of the STN customer
 agreement. This agreement limits use to scientific research. Use
 for software development or design, implementation of commercial
 gateways, or use of CAS and STN data in the building of commercial
 products is prohibited and may result in loss of user privileges
 and other penalties.

****
*   *
* Please take a couple of minutes to complete our short survey. Your *
* name will be entered to win one of five $20 Amazon.com gift cards. *
*   *
* See NEWS 14 for details or go directly to the survey at: *
* http://www.zoomerang.com/Survey/?p=WEB229H4S8Q5UL   *
*   *
****

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:14:52 ON 18 AUG 2009

=> file caplus
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                               ENTRY   SESSION
FULL ESTIMATED COST   0.22   0.22

FILE 'CAPLUS' ENTERED AT 16:15:06 ON 18 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is

strictly prohibited.

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2009.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family
of databases have been updated to include new citing references
information. This enhancement may impact record import into
database management software. For additional information, refer
to NEWS 9.

```
=> s (glypican-3 or GPC3 or DGSX or GTR2-2 or MXR7 or OCI5 or SDYS or SGB or
SGBS or SGBS1) and  melanoma
        731 GLYPICAN
        352 GLYPICANS
        791 GLYPICAN
            (GLYPICAN OR GLYPICANS)
     7705968 3
        310 GLYPICAN-3
            (GLYPICAN(W)3)
        283 GPC3
          0 DGSX
         24 GTR2
    10178478 2
          3 GTR2-2
            (GTR2(W)2)
         11 MXR7
          7 OCI5
          1 SDYS
        251 SGB
         62 SGBS
        307 SGB
            (SGB OR SGBS)
         62 SGBS
```

```
        3 SGBS1
     42855 MELANOMA
      4189 MELANOMAS
        19 MELANOMATA
     43425 MELANOMA
           (MELANOMA OR MELANOMAS OR MELANOMATA)
L1      50 (GLYPICAN-3 OR GPC3 OR DGSX OR GTR2-2 OR MXR7 OR OCI5 OR
SDYS
           OR SGB OR SGBS OR SGBS1) AND  MELANOMA

=> duplicate remove L1
PROCESSING COMPLETED FOR L1
L2      50 DUPLICATE REMOVE L1 (0 DUPLICATES REMOVED)

=> s L2 (S) (diagnos? or assay? or measur? or detect?)
L3      50 S L2
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'L3 (S) '
      363581 DIAGNOS?
      655862 ASSAY?
      3406766 MEASUR?
      2007938 DETECT?
L4      30 L3 (S) (DIAGNOS? OR ASSAY? OR MEASUR? OR DETECT?)

=> s (glypican-3 or GPC3 or DGSX or GTR2-2 or MXR7 or OCI5 or SDYS or SGB or
SGBS or SGBS1) (S) melanoma
      731 GLYPICAN
      352 GLYPICANS
      791 GLYPICAN
         (GLYPICAN OR GLYPICANS)
   7705968 3
      310 GLYPICAN-3
         (GLYPICAN(W)3)
      283 GPC3
        0 DGSX
       24 GTR2
   10178478 2
        3 GTR2-2
         (GTR2(W)2)
       11 MXR7
        7 OCI5
        1 SDYS
      251 SGB
       62 SGBS
      307 SGB
         (SGB OR SGBS)
```

```
      62 SGBS
       3 SGBS1
   42855 MELANOMA
    4189 MELANOMAS
      19 MELANOMATA
   43425 MELANOMA
        (MELANOMA OR MELANOMAS OR MELANOMATA)
L5      20 (GLYPICAN-3 OR GPC3 OR DGSX OR GTR2-2 OR MXR7 OR OCI5 OR
SDYS
        OR SGB OR SGBS OR SGBS1) (S) MELANOMA

=> duplicate remove L5
PROCESSING COMPLETED FOR L5
L6      20 DUPLICATE REMOVE L5 (0 DUPLICATES REMOVED)

=> s L6 (S) (DIAGNOS? OR ASSAY? OR MEASUR? OR DETECT?)
L7      20 S L6
    363581 DIAGNOS?
    655862 ASSAY?
   3406766 MEASUR?
   2007938 DETECT?
L8       9 L7 (S) (DIAGNOS? OR ASSAY? OR MEASUR? OR DETECT?)

=> d L8 bib abs 1-9
```

AB   A review. Glypican-3 (GPC3) is a heparan sulfate proteoglycan that plays
     an important role in cell growth and differentiation. GPC3 function is
     tissue dependent. In some tissues, GPC3 acts as a tumor suppressor gene,
     whereas in others, it acts as an oncofetal protein. Studies have shown
     that GPC3 is a reliable marker for hepatocellular carcinoma. The
     sensitivity and specificity exceeds both .alpha.-fetoprotein and
     hepatocyte-paraffin1. GPC3 immunohistochem. can aid in the
     differentiation of testicular germ cell tumors, being expressed in all
     yolk sac tumors but not in seminomas. GPC3 expression has also been

identified in some squamous cell carcinomas of the lung and clear cell
carcinomas of the ovary. The role of GPC3 in melanomas is still
controversial. This article reviews the current information on the
application of GPC3 immunostaining in surgical pathol. and cytol.
RE.CNT 41   THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS
RECORD
      ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:407710 CAPLUS
DN 146:375330
TI Cancer metastasis diagnosis method, and therapeutic drug
IN Oguchi, Masao; Ishii, Keisuke
PA Perseus Proteomics Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 18pp.
   CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2007093274	A	20070412	JP 2005-279913	20050927
PRAI JP 2005-279913		20050927		

AB Provided is a method for diagnosing cancer selected from Ewing's sarcoma
primary nest, Ewing's sarcoma metastasis tissue, melanoma metastasis
tissue and hepatic carcinoma metastasis tissue. The diagnostic method is
characterized in that it comprises detecting GPC3 protein in a test sample
(e.g., blood, blood serum, blood plasma) by an immunoassay using an
anti-GPC3 antibody. Also provided is a diagnostic agent or
therapeutic drug for metastatic cancer selected from Ewing's sarcoma
primary nest, Ewing's sarcoma metastasis tissue, melanoma
metastasis tissue and hepatic carcinoma metastasis tissue, which is
characterized in that it containes resp. a GPC3 protein
detection reagent contg. an anti-GPC3 antibody, or an
anti-GPC3 antibody.

L8 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:383728 CAPLUS
DN 144:431112
TI Anti-SPARC and anti-glypican-33 antibodies and test kits for diagnosis of
hepatic cancer and melanoma
IN Nishimura, Yasuharu; Nakatsura, Tetsuya; Ikuta, Yoshiaki
PA Kumamoto University, Japan
SO PCT Int. Appl., 24 pp.
   CODEN: PIXXD2
DT Patent

LA Japanese
FAN.CNT 1

PATENT NO.   KIND DATE   APPLICATION NO.   DATE
  --------------   ---- -------   -------------------- --------
PI WO 2006043362   A1 20060427 WO 2005-JP14567   20050809
    W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
      CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
      GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
      LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
      NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
      SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
      ZA, ZM, ZW
    RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
      IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
      CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
      GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
      KG, KZ, MD, RU, TJ, TM
  AU 2005297303   A1 20060427 AU 2005-297303   20050809
  EP 1813943   A1 20070801 EP 2005-770440   20050809
    R: DE, FR, GB
  US 20090111095   A1 20090430 US 2008-577435   20081212
PRAI JP 2004-303688   A 20041019
  WO 2005-JP14567   W 20050809
AB It is intended to find another tumor marker useful for the early diagnosis
  of melanoma and to provide, utilizing the same, a diagnostic kit for
  malignant melanoma and method of diagnosis therefor. There is provided a
  diagnostic kit for malignant melanoma, comprising an
  antibody against SPARC and an antibody against GPC3.
OSC.G 1   THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1
CITINGS)
RE.CNT 2   THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD
      ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:39388 CAPLUS
DN 144:228826
TI Melanoma antigen gene family D 1 protein as hepatocarcinoma marker and its
  application in cancer diagnosis
IN Wan, Dafang; Gu, Jianren; Yang, Shengli
PA Shanghai New World Gene Technology Development Co., Ltd., Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 22 pp.
  CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

```
  PATENT NO.      KIND  DATE     APPLICATION NO.      DATE
  ---------------  ----  --------  --------------------  --------
PI  CN 1629637     A    20050622  CN 2003-10109398    20031215
    CN 1281962     C    20061025
PRAI CN 2003-10109398         20031215
```

AB   This invention relates to melanoma antigen gene family D1 protein (MAGFD1)
     as hepatocarcinoma marker, test kit and protein chip contg. anti-MAGED1
     specific antibody for diagnosing hepatocarcinoma. The protein chip can
     also contains antibodies against other antigens, such as pTEN, p21, p27,
     p73, p53, Rb1, APC, nm23, P16, MXR7, IGF-II, TGF.alpha., HGF-R, c-erbB-1,
     Ras, Raf, c-myc and c-ets-2. This invention also describes medicine
     contg. antagonist of MAGFD1 and pharmaceutically acceptable carriers.
OSC.G 1   THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1
CITINGS)

L8   ANSWER 5 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
AN   2005:1234417 CAPLUS
DN   144:251411
TI   Highly Sensitive Detection of Melanoma at an Early
     Stage Based on the Increased Serum Secreted Protein Acidic and Rich in
     Cysteine and Glypican-3 Levels
AU   Ikuta, Yoshiaki; Nakatsura, Tetsuya; Kageshita, Toshiro; Fukushima,
     Satoshi; Ito, Shosuke; Wakamatsu, Kazumasa; Baba, Hideo; Nishimura,
     Yasuharu
CS   Department of Immunogenetics, Graduate School of Medical Sciences,
     Kumamoto University, Kumamoto, Japan
SO   Clinical Cancer Research (2005), 11(22), 8079-8088
     CODEN: CCREF4; ISSN: 1078-0432
PB   American Association for Cancer Research
DT   Journal
LA   English
AB   PURPOSE: There are no available tumor markers detecting primary melanoma
     at an early stage. The identification of such serum markers would be of
     significant benefit for an early diagnosis of melanoma. We recently
     identified glypican-3 (GPC3) as a novel
     tumor marker but could diagnose only 40% of melanomas.
     Thereby, we focused out attention on secreted protein acidic and rich in
     cysteine (SPARC) overexpressed in melanoma as another candidate for tumor
     marker. Exptl. Design: Secreted SPARC protein was quantified using ELISA
     in the sera from 109 melanoma patients, five patients with large
     congenital melanocytic nevus, 61 age-matched healthy donors, and 13
     disease-free patients after undergoing a surgical removal. We also
     quantified GPC3 and 5-S-cysteinyldopa in the same serum samples and
     compared these markers for their diagnostic value. RESULTS: The serum
     SPARC concns. in melanoma patients were greater than those in healthy
     donors (P = 0.001). When we fixed a cutoff value at the mean concn. plus

2 SD of the healthy donors, the serum SPARC was found to have increased in the sera of 36 of the 109 (33%) melanoma patients, whereas there were three (4.9%) false-pos. cases of 61 healthy donors. Surprisingly, 19 of 36 patients showing increased SPARC levels were in stages 0 to II. The serum SPARC level decreased under the cutoff level in 10 of 13 patients after surgical removal. Using SPARC and GPC3 in combination thus enabled us to diagnose 47 of 75 (66.2%) melanoma patients at an early stage (0-II). CONCLUSIONS: SPARC or its combination with GPC3 is thus considered a potentially useful tumor marker, esp. for melanoma at an early stage.

L8 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
AN   2005:448336 CAPLUS
DN   143:170230
TI   Usefulness of the novel oncofetal antigen glypican-3
     for diagnosis of hepatocellular carcinoma and melanoma
AU   Nakatsura, Tetsuya; Nishimura, Yasuharu
CS   Department of Immunogenetics, Graduate School of Medical Sciences,
     Kumamoto University, Kumamoto, Japan
SO   BioDrugs (2005), 19(2), 71-77
     CODEN: BIDRF4; ISSN: 1173-8804
PB   Adis International Ltd.
DT   Journal; General Review
LA   English
AB   A review. Discussed are: novel strategies for identification of
     tumor-assocd. antigens; identification and expression of glypican (GPC)-3
     in hepatocellular carcinoma and melanoma; detection of GPC-3 in patients;
     and known biol. properties of GPC-3.

L8 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2009 ACS on STN
AN   2005:395015 CAPLUS
DN   142:426401
TI   Diagnostic agent for malignant melanoma
IN   Nishimura, Yasuharu; Nakatsura, Tetsuya
PA   Kumamoto Technology & Industry Foundation, Japan
SO   PCT Int. Appl., 26 pp.

```
   CODEN: PIXXD2
DT  Patent
LA  Japanese
FAN.CNT 1
   PATENT NO.       KIND  DATE       APPLICATION NO.      DATE
   --------------   ----  --------   -------------------- --------
PI WO 2005039380      A2   20050506  WO 2004-JP16374       20041028
   WO 2005039380      A3   20050630
     W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
        CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
        GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
        LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
        NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
        TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
     RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
        AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
        EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
        SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
        SN, TD, TG
   AU 2004283614      A1   20050506  AU 2004-283614        20041028
   EP 1684076         A2   20060726  EP 2004-793354        20041028
   EP 1684076         B1   20081231
     R: CH, DE, FR, GB, LI, NL
   CN 1894587         A    20070110  CN 2004-80032204      20041028
   US 20080044818     A1   20080221  US 2007-577343        20070305
PRAI JP 2003-368725      A    20031029
   WO 2004-JP16374      W    20041028
AB  A novel and clin. useful diagnostic agent for malignant melanoma.  There
   is provided a diagnostic agent for malignant melanoma,
   comprising an antibody against GPC3, or a primer or probe
   capable of detecting the expression of GPC3.
RE.CNT 2    THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD
       ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8  ANSWER 8 OF 9  CAPLUS  COPYRIGHT 2009 ACS on STN
AN  2004:1150198 CAPLUS
DN  142:278355
TI  Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes
   T-cell-mediated tumor rejection without autoimmune reactions in mice
AU  Nakatsura, Tetsuya; Komori, Hiroyuki; Kubo, Tatsuko; Yoshitake, Yoshihiro;
   Senju, Satoru; Katagiri, Toyomasa; Furukawa, Yoichi; Ogawa, Michio;
   Nakamura, Yusuke; Nishimura, Yasuharu
CS  Departments of Immunogenetics, Kumamoto University, Kumamoto, Japan
SO  Clinical Cancer Research (2004), 10(24), 8630-8640
   CODEN: CCREF4; ISSN: 1078-0432
```

PB   American Association for Cancer Research
DT   Journal
LA   English
AB   The authors recently identified glypican-3 (GPC3) overexpressed
     specifically in human hepatocellular carcinoma, as based on cDNA
     microarray anal. of 23,040 genes, and the authors reported that GPC3 is a
     novel tumor marker for human hepatocellular carcinoma and melanoma. GPC3,
     expressed in almost all hepatocellular carcinomas and melanomas, but not
     in normal tissues except for placenta or fetal liver, is a candidate of
     ideal tumor antigen for immunotherapy. In this study, the authors
     attempted to identify a mouse GPC3 epitope for CTLs in BALB/c mice, and
     for this, the authors set up a preclin. study to investigate the
     usefulness of GPC3 as a target for cancer immunotherapy in vivo. The
     authors identified a mouse GPC3-derived and Kd- restricted CTL epitope
     peptide in BALB/c mice. Inoculation of this GPC3 peptide-specific CTL
     into s.c. Colon26 cancer cells transfected with mouse GPC3 gene (C26/GPC3)
     led to rejection of the tumor in vivo, and i.v. inoculation of these CTLs
     into sublethally irradiated mice markedly inhibited growth of an
     established s.c. tumor. Inoculation of bone marrow-derived dendritic
     cells pulsed with this peptide prevented the growth of s.c. and splenic
     C26/GPC3 accompanied with massive infiltration of CD8+ T cells into
     tumors. Evidence of autoimmune reactions was never obsd. in surviving
     mice that had rejected tumor cell challenges. The authors found the novel
     oncofetal protein GPC3 to be highly immunogenic in mice and elicited
     effective antitumor immunity with no evidence of autoimmunity.
     GPC3 is useful not only for diagnosis of hepatocellular
     carcinoma and melanoma but also for possible immunotherapy or
     prevention of these tumors.

AN   2004:827193 CAPLUS
DN   142:4152
TI   Identification of glypican-3 as a novel tumor marker for melanoma
AU   Nakatsura, Tetsuya; Kageshita, Toshiro; Ito, Shosuke; Wakamatsu, Kazumasa;
     Monji, Mikio; Ikuta, Yoshiaki; Senju, Satoru; Ono, Tomomichi; Nishimura,
     Yasuharu
CS   Department of Immunogenetics, Graduate School of Medical Sciences,
     Kumamoto University, Kumamoto, Japan
SO   Clinical Cancer Research (2004), 10(19), 6612-6621
     CODEN: CCREF4; ISSN: 1078-0432
PB   American Association for Cancer Research

DT   Journal

LA   English

AB   The authors reported recently the novel tumor marker glypican-3 (GPC3) for
hepatocellular carcinoma. In the present study, the authors investigated
the expression of GPC3 in human melanoma cell lines and tissues and asked
whether GPC3 could be a novel tumor marker for melanoma. Expression of
GPC3 mRNA and protein was investigated in human melanoma cell lines and
tissues using reverse transcription-PCR and immunohistochem. anal.
Secreted GPC3 protein was quantified using ELISA in culture supernatants
of melanoma cell lines and in sera from 91 patients with melanoma and 28
disease-free patients after surgical removal of primary melanoma. All of
the subjects were Japanese nationals. In >80% of melanoma and melanocytic
nevus, there was evident expression of GPC3 mRNA and protein.
Furthermore, GPC3 protein was evidenced in sera of 39.6% (36 of 91) of
melanoma patients but not in sera from subjects with large congenital
melanocytic nevus (0 of 5) and from healthy donors (0 of 60).
Twenty-seven of 36 serum GPC3-pos. patients were neg. for both serum
5-S-cysteinyldopa and melanoma-inhibitory activity, well-known tumor
markers for melanoma. The pos. rate of serum GPC3 (39.6%) was
significantly higher than that of 5-S-cysteinyldopa (26.7%) and of
melanoma-inhibitory activity (20.9%). Surprisingly, the authors
detected serum GPC3 even in patients with stage 0 in
situ melanoma. The pos. rate of serum GPC3 at stage 0, I, and
II (44.4%, 40.0%, and 47.6%) was significantly higher than that of
5-S-cysteinyldopa (0.0%, 8.0%, and 10.0%). Also obsd. was the
disappearance of GPC3 protein in sera from 11 patients after surgical
removal of the melanoma. GPC3 is apparently a novel tumor
marker useful for the diagnosis of melanoma, esp. in
early stages of the disorder.

OSC.G 33   THERE ARE 33 CAPLUS RECORDS THAT CITE THIS RECORD (33
CITINGS)

RE.CNT 38   THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS
RECORD

      ALL CITATIONS AVAILABLE IN THE RE FORMAT